Future experiments will be needed to determine whether chronic inhibition of TTBK1, presumably over the course of several months, would ameliorate the cognitive deficits demonstrated in tau transgenic models of disease [63,64]. The gene discussed is MAPT; the disease is Cognitive impairment.